investigated a novel Pickering emulsion gel (APEG) loaded with oxaliplatin (OXA) and the LDHA inhibitor GSK2837808A (GSK) to confirm that the combination formulation can effectively enhance drug delivery efficiency and boost anti-tumor therapy by activating the tumor immune microenvironment and increasing the infiltration of CD8+T cells (196). Here, CD8A is linked to neoplasm.